25 jun: North Media A/S opjusterer forventningerne til 2019
26 jun: DSV, 759 - DSV forlænger ombytningsperiode for Panalpina aktier
25-06-2019 19:56:06

Major Shareholder Announcement

Company Announcement

  • Major shareholder announcement for Genmab A/S

Copenhagen, Denmark; June 25, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of June 21, 2019, BlackRock, Inc. has decreased their total ownership (indirectly owned shares and financial instruments) in Genmab A/S to 3,067,468 shares, which amounts to 4.97% of the share capital and voting rights in Genmab A/S.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 29

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
19 jul - 
Fredagens aktier: Pandora fik stryg på børsen og tynged..
19 jul - 
Aktier/middag: Halter efter Europa trods plusser - især..
19 jul - 
Aktier/åbning: Ørsted dribler eliteindekset i plus
Relateret debat
10:15 - 
Ja der er så +10 år til og hvis Genmab mene..
09:19 - 
Altafgørende bliver om udløbsdatoen for D..
09:14 - 
Enig i det er en udvanding. Men trods alt bedre at skaf..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jul
GEN
Hmm. Det er med blandede følelser jeg for tid til anden følger med i Genmab trådende. Da Genmab s b..
18
16 jul
GEN
Med markering:   https://ir.genmab.com/news-releases/news-release-details/genmab-announces-net-sales..
7
16 jul
GEN
Evt godkendelse forventes ultimo 2019 og på markedet  Q1 20 SC-behandlingen bliver sandsynligvis væs..
5
16 jul
GEN
Markedsværdi ca. 75 mia for hele butikken svarer vel stort set til den pris som Celgene for ca. 2 år..
5
19 jul
GEN
Mon vi skal igennem de 1234 idag    https://www.euroinvestor.dk/nyheder/2019/07/19/genmab-barclays-s..
4
16 jul
GEN
Nogle analytikere påpeger at trækker man valuta og engangs pillerier ud, så er det som forventet, do..
4
10:15
GEN
Ja der er så +10 år til og hvis Genmab mener de kunne få brug for +500 mil vil jeg mene det er bedre..
3
21 jul
GEN
Enhver kap udv er altid en udvanding. Alle nøgletal vil blive ramt af at der er flere aktier uden de..
3
19 jul
GEN
Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for..
3
16 jul
GEN
"en grådig ledelse som man tænker vil gøre alt for at øge kursen"   Den er jeg med på. 
3

Italienske Unicredit vil skære op mod 10.000 job i ny strategiplan

22-07-2019 12:41:42
Den italienske bank Unicredit overvejer ifølge kilder med indblik i sagen at skære tusindvis af job og trimme driftsomkostningerne som en del af bankens nye strategiplan.Det skriver Bloomberg News.Den italienske bank overvejer ifølge nyhedsbureauets kilder, som har bedt om ikke at blive identificeret med navn, at skære op mod 10.000 job, men de eksakte tal er endnu under overvejelse og kan ende me..

Ørsted: "Det er gået bedre i USA end vi turde håbe"

22-07-2019 10:15:02
Det amerikanske marked for havvind blev hurtigt udråbt til at være et stort potentielt vækstmarked hos den danske energikoncern Ørsted, men starten på eventyret i USA gik ikke helt så glat, som man kunne have håbet.I hvert fald endte det danske selskab sidste år med at gå tomhændet hjem efter de første udbudsrunder for havvindprojekter i USA, hvor Ørsteds konkurrenter i stedet løb med de første se..

Teknologi-rally bag rekordgevinster i aktiemarkedet

Relaterede nyheder
22-07-2019 09:19:50
De største teknologiselskaber står bag de amerikanske aktieindeks-rekorder, hvilket fremhæver entusiasmen hos investorer for den attraktive sektor, i takt med at den økonomiske vækst viger.Det skriver The Wall Street Journal.Tilsammen har Microsoft, Apple, Amazon.com og Facebook stået for 19 pct. af S&P 500-indeksets samlede afkast i år. Det har resulteret i, at flere store investeringsselskaber, ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank: Flere finanshuse sænker kursmål efter regnskab
2
Teknologi-rally bag rekordgevinster i aktiemarkedet
3
Aktier/tendens: Olieprisen kan påvirke Maersk Drilling i rolig start
4
Danmark/Sydbank: Tal for beskæftigelsen er en smule bekymrende
5
Aktier/middag: Børshuse lægger nyt pres på bankaktierne

Relaterede aktiekurser

Genmab A/S 1.214,50 -0,4% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. juli 2019 15:53:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB7 - 2019-07-22 15:53:49 - 2019-07-22 15:53:49 - 1 - Website: OKAY